©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 114021
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.114021
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.114021
Clinicopathologic features of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma: A case report and review of literature
Wan-Qi Yao, Gui-Hua Wang, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 311112, Zhejiang Province, China
Xin-Yi Ma, Department of Pathology, Pathological Diagnosis Center of Dian Diagnostic Te
Author contributions: Yao WQ obtained all the required data and drafted the article after literature review; Ma XY responsible for performing immunohistochemical staining; Wang GH critically revised the article and approved the final version of the article.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this article and any accompanying data.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Gui-Hua Wang, MD, Professor, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, No. 1260 Kangliang Street, Liangzhu Street, Hangzhou 311112, Zhejiang Province, China. mamaninghao@163.com
Received: September 11, 2025
Revised: November 2, 2025
Accepted: December 1, 2025
Published online: January 15, 2026
Processing time: 124 Days and 0.9 Hours
Revised: November 2, 2025
Accepted: December 1, 2025
Published online: January 15, 2026
Processing time: 124 Days and 0.9 Hours
Core Tip
Core Tip: SMARCB1-deficient undifferentiated rhabdoid carcinoma of the pancreas represents a highly aggressive and rare neoplasm. This study suggests that aggressive multimodal therapy, including surgical resection and chemotherapy, may prolong survival in selected patients; however, the overall prognosis remains poor. Given its distinct molecular characteristics and potential resistance to standard therapies, further research into targeted treatment approaches and prospective clinical studies is urgently warranted.